Metrics as of 10/13/2026, 06:40 PM (Berlin time), refresh in progress.
BioMarin Pharmaceutical Stock
BioMarin Pharmaceutical Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Alexander Hardy
- Employees
- 3,221
- Market cap
- $10.5 B
- IPO
- 26/07/1999
BioMarin Pharmaceutical Inc. is a healthcare company headquartered in San Rafael, US, specializing in the creation and marketing of treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions. The company's product portfolio includes several key pharmaceuticals…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
BioMarin Pharmaceutical stock: price history
1D
-1.8%
1W
-3.3%
1M
-17.2%
6M
-2.0%
YTD
-8.5%
1Y
+3.7%
2Y
-22.7%
5Y
-30.1%
10Y
-36.1%
Next earnings date
Next earnings date
26/10/2026 (in 9 days)
Volatility around earnings
~0% stronger price swings than usual
Ask the agents about BioMarin Pharmaceutical
Analyst assessment of BioMarin Pharmaceutical
PRICE TARGET LOW
US$59.00
CONSENSUS
US$90.88
MEDIAN
US$90.00
PRICE TARGET HIGH
US$124.00
0
STRONG BUY
29
BUY
12
HOLD
0
SELL
0
STRONG SELL
41
TOTAL · Buy
As of: 10/09/2026
BioMarin Pharmaceutical stock metrics
P/E
143.11
P/B
1.66
EV/EBITDA
35.88
RETURN ON EQUITY
0.7%
NET MARGIN
4.5%
DEBT/EQUITY
0.66
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
99.4%
FLOAT SHARES
192,093,806
AVG. DAILY VOLUME (30D)
2,156,336
Insider transactions (SEC)
Friberg Gregory R
Plenge Robert M
Davis George Eric
Dere Willard H
Enyedy Mark J
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -1.8%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about BioMarin Pharmaceutical stock
What does BioMarin Pharmaceutical do?
BioMarin Pharmaceutical Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Alexander Hardy, the company employs around 3,221 people.
The IPO was on 26/07/1999; the stock trades on NASDAQ under the ticker BMRN.
What do analysts say about BioMarin Pharmaceutical stock?
41 analysts rate the stock, the consensus is Buy (as of 10/09/2026).
The average price target is US$90.88, ranging from US$59.00 to US$124.00, with a median of US$90.00.
This is an external assessment, not a statement by Market Jury.
When does BioMarin Pharmaceutical report next?
The next earnings date is 26/10/2026.
Around past earnings, price swings were roughly 0% stronger than usual.
Does BioMarin Pharmaceutical pay a dividend?
No, BioMarin Pharmaceutical currently does not pay a dividend.
Which stocks are comparable to BioMarin Pharmaceutical?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get BioMarin Pharmaceutical stock analyzed?
Clicking "Analyze stock" lets five strategies assess BioMarin Pharmaceutical against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.